Do any of the early trials in advanced cancers aspire to be great?
Not in Chicago – Of relevance to the ongoing ASCO20 coverage, in the Preview series this year, two of the companies we highlighted going into the meeting (Innovent and Alphamab) both announced deals this week with Roche and Sanofi, respectively – talk about highlighting hot topics ahead of time 😉
After last week’s look at winners and losers in hematologic malignancies, this time around we now turn our attention to explore what’s happening on the new product development front regarding solid tumours. In this review, we critique some of the trials presented and put them in broader context.
As always, there are both some important learnings we can glean as well as some, well, head/desk moments to contemplate…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
With so much data to cover recently, we haven’t have time for a perennial favourite, the monthly mailbag to answer BSB reader Q&A on hot oncology topics.
October has brought out quite a lot of controversy to consider, most of it happening in the last week!
Here, we consider questions on Immune Design’s phase 3 trial with their NY-ESO-1 vaccine, CMB305, which attracted both a lot of market attention and also questions from readers.
We also review a bunch of questions relating to 1L NSCLC and the upcoming readouts. This niche is probably potentially one of the most competitive spaces in oncology R&D at present and readers seem almost insatiable for information on this topic.
It is quite a turnaround considering the last decade of numerous failed trials or even non-inferiority studies that were being conducted.
Like many readers, I can well remember sitting in freezing cold, half empty halls wondering if the latest chemo or targeted therapy doublet was going to offer a mere 2-3 months improvement in PFS and no OS benefit or not. It was that binary and also depressing.
With the possibilities offered by immune checkpoint blockade, in a short space of time 1L NSCLC has gone from graveyard to uber intense with several companies vying to demonstrate improvements in overall survival by 6 months or more.
There’s a lot more to come here and not all of the lung trials will be positive – that’s expecting too much against the game of chance. Here, we look at numerous factors that could make a difference, both positive and negative.
To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.
Yesterday, we had a sarcoma expert in the spotlight looking at the new developments from the American Society of Clinical Oncology (ASCO).
In part two of our sarcoma mini-series, we have another interview for our readers, this time from the perspective of the CEO, Dr Carlos Paya. They had some interesting data in Chicago so what was their reaction to it and where are they going next?
To learn more subscribers can log-in or you can purchase access to BSB Premium Content.